Transcatheter Arterial Chemoembolization for Treatment-Naive Hepatocellular Carcinoma Has Different Treatment Effects Depending on Central or Peripheral Tumor Location.
Hepatocellular carcinoma
Predictive factor
Systemic chemotherapy
Transcatheter arterial chemoembolization
Treatment response
Journal
Liver cancer
ISSN: 2235-1795
Titre abrégé: Liver Cancer
Pays: Switzerland
ID NLM: 101597993
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
15
09
2022
accepted:
27
03
2023
medline:
7
12
2023
pubmed:
7
12
2023
entrez:
7
12
2023
Statut:
epublish
Résumé
The purpose of this study was to evaluate the treatment efficacy of transcatheter arterial chemoembolization (TACE) for treatment-naive hepatocellular carcinoma (HCC) according to tumor location and burden. Between 2010 and 2019, consecutive patients who underwent TACE as the first treatment were enrolled. Tumors were classified into two categories based on their location, as central or peripheral tumors. Tumors in the central zone, which is within 1 cm of the main trunk or the first branch of the portal vein, were classified as central tumors, while those located in the peripheral zone were classified as peripheral tumors. Patients were grouped according to the HCC location and up-to-7 criteria. Patients with central tumors were classified into the central arm and those with only peripheral tumors were classified into the peripheral arm. Patients within and beyond the up-to-7 criteria were classified into the up-to-7 in and up-to-7 out-groups, respectively. Local recurrence-free survival (LRFS) and progression-free survival (PFS) were compared per nodule (central tumor vs. peripheral tumor) and per patient (central arm vs. peripheral arm), respectively. The prognostic factors of LRFS and PFS were analyzed by univariate and multivariate analyses. A total of 174 treatment-naive patients with 352 HCCs were retrospectively enrolled. Ninety-six patients and 130 lesions were selected by propensity score matching. Median LRFS was longer for peripheral tumors than central tumors (not reached vs. 3.3 months, Treatment-naive HCCs in the peripheral zone had a longer LRFS and PFS following TACE compared to those in the central zone.
Identifiants
pubmed: 38058422
doi: 10.1159/000530441
pii: 530441
pmc: PMC10697731
doi:
Types de publication
Journal Article
Langues
eng
Pagination
576-589Informations de copyright
© 2023 The Author(s). Published by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Liver Cancer. 2021 Jul 22;10(6):629-640
pubmed: 34950185
Liver Int. 2016 Jan;36(1):92-9
pubmed: 25950442
Ann Oncol. 2013 Oct;24(10):2565-2570
pubmed: 23857958
Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565-575
pubmed: 28648803
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Liver Cancer. 2021 Jun;10(3):181-223
pubmed: 34239808
Cardiovasc Intervent Radiol. 2020 Mar;43(3):423-433
pubmed: 31720806
Liver Cancer. 2020 Jun;9(3):245-260
pubmed: 32647629
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
Liver Cancer. 2022 Jun 15;11(5):440-450
pubmed: 36158586
J Hepatol. 2015 Jul;63(1):122-30
pubmed: 25725438
Cancer Sci. 2009 Jan;100(1):173-80
pubmed: 19037999
Gut. 2020 Aug;69(8):1492-1501
pubmed: 31801872
J Chin Med Assoc. 2008 Oct;71(10):523-7
pubmed: 18955187
Eur Radiol. 2016 Jun;26(6):1640-8
pubmed: 26455721
World J Gastroenterol. 2015 Oct 7;21(37):10604-8
pubmed: 26457020
Dig Dis Sci. 2013 Jun;58(6):1758-65
pubmed: 23361574
Eur J Cancer. 2011 Sep;47(14):2117-27
pubmed: 21664811
J Hepatol. 2019 May;70(5):893-903
pubmed: 30660709
HPB (Oxford). 2014 Apr;16(4):327-35
pubmed: 23980917
World J Gastroenterol. 2004 Oct 1;10(19):2878-82
pubmed: 15334691
AJR Am J Roentgenol. 2013 May;200(5):1160-6
pubmed: 23617505
Dig Liver Dis. 2013 Apr;45(4):336-41
pubmed: 23245589
Science. 2005 Jan 7;307(5706):58-62
pubmed: 15637262
Eur J Radiol. 2012 Feb;81(2):e158-65
pubmed: 21315528
Liver Cancer. 2021 Feb;10(1):63-71
pubmed: 33708640
J Hepatol. 2016 May;64(5):1090-1098
pubmed: 26809111
Hepatology. 2020 Jul;72(1):198-212
pubmed: 31698504
Hepatology. 2014 Nov;60(5):1697-707
pubmed: 24996197
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Radiology. 1983 Aug;148(2):397-401
pubmed: 6306721
Liver Cancer. 2018 Sep;7(3):215-224
pubmed: 30319981
Liver Int. 2019 Sep;39(9):1704-1712
pubmed: 31319016
Liver Cancer. 2021 Feb;10(1):38-51
pubmed: 33708638
Liver Int. 2016 Jan;36(1):100-7
pubmed: 26013186
J Hepatol. 2022 Mar;76(3):681-693
pubmed: 34801630
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
Liver Cancer. 2015 Dec;4(4):253-62
pubmed: 26734579
Hepatology. 2011 May;53(5):1580-9
pubmed: 21351114
Oncol Lett. 2020 Sep;20(3):2257-2265
pubmed: 32782543
Korean J Radiol. 2007 Mar-Apr;8(2):111-9
pubmed: 17420628
Liver Int. 2017 Dec;37(12):1861-1868
pubmed: 28581250
Liver Int. 2016 May;36(5):729-36
pubmed: 26604044
Lancet Gastroenterol Hepatol. 2018 Jan;3(1):37-46
pubmed: 28988687
Lancet Oncol. 2009 Jan;10(1):35-43
pubmed: 19058754
PLoS One. 2015 Apr 28;10(4):e0125244
pubmed: 25919025
Int J Clin Oncol. 2022 Jul;27(7):1110-1119
pubmed: 35527313
Cancers (Basel). 2019 Jul 31;11(8):
pubmed: 31370183
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Hepatology. 2011 Jan;53(1):136-47
pubmed: 20967759
Clin Gastroenterol Hepatol. 2015 Jun;13(6):1204-8.e2
pubmed: 25528009
Gut Liver. 2017 May 15;11(3):409-416
pubmed: 28208001
J Vasc Interv Radiol. 2013 Apr;24(4):509-17
pubmed: 23428355
Hepatol Res. 2020 Oct;50(10):1176-1185
pubmed: 32721060
J Hepatol. 2014 Dec;61(6):1287-96
pubmed: 25016222
Jpn J Radiol. 2019 Jul;37(7):543-548
pubmed: 31055710
Semin Liver Dis. 2012 Nov;32(4):348-59
pubmed: 23397536